Generics

Press enter to search
Close search
Open Menu

Generics

News and information on generic drugs sold in retail pharmacies, as well as their suppliers.

A man holding an FDA approved sign.

Glenmark gets FDA OK for generic Zytiga

Zytiga tablets, 250 mg had a market value of $794.1 million for the 12 month period ended August 2019, according to IQVIA.

An assortment of generic capsules and pills.

ANI launches generic Aggrenox

Aspirin and extended-release dipyridamole capsules have a market value of roughly $80 million.

A man holding an FDA approved sign.

Betamethasone dipropionate lotion (augmented), 0.05% had a market value of approximately $10 million for the 12 months ended August 2019, according to IQVIA.

A pill bottle with no label against a blue background.

Tecfidera capsules, 120 mg and 240 mg had a market value of approximately $3.7 billion for the 12 months ended in August 2019.

injectable vials

Pfizer is planning to launch its Avastin biosimilar, Zirabev, on Dec. 31, according to a

A pill bottle with no label in a person's hand.

Paliperidone extended-release tablets had a market value of approximately $373 million for the 12 months ended July 31.

Alembic Pharmaceuticals is introducing its first ophthalmic glaucoma product.

Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, so that it doesn't require refrigeration.

A man holding an FDA approved sign.

The FDA has approved Zydus Cadila's generic cholesterol-lowering drug.

A man holding an FDA approved sign.

Forteo had a global market value of $1.6 billion in 2018.

The Association for Accessible Medicines released a white paper highlighting new data on the treatment of generic medicines in Medicare Part D.

Under the agreement, Lanett will begin U.S. distribution of Respirent’s generic once the product receives the Food and Drug Administration’s approval.

Perrigo generic Transderm Scoop

Transderm Scop and generics had a market value of roughly $147 million for the 12 months ending August 2019.

Sun Pharma has received the Food and Drug Administration’s approval for risedronate delayed-release tablets in a dosage strength of 35 mg. The product is the generic of Actavis’ Atelvia. Risedronate delayed-release 35mg tablets have a market value of $17 million, according to IQVIA. The pr

Show More